Takeda Pharmaceutical (TAK) Equity Income (2018 - 2020)

Takeda Pharmaceutical's Equity Income history runs 3 years deep, the most recent figure standing at $5.3 billion for Q3 2020.

• On a quarterly basis, Equity Income changed N/A year-over-year to $5.3 billion in Q3 2020; TTM through Sep 2020 was $6.5 billion, a N/A change from a year earlier, with the FY2020 full-year figure at $1.8 billion, up 560.91% from the prior year.
• Equity Income rose to $5.3 billion in Q3 2020 per TAK's latest filing, from $1.8 billion in the prior quarter.
• Across five years, Equity Income topped out at $5.3 billion in Q3 2020 and bottomed at -$604.7 million in Q1 2018.
• The 3-year median for Equity Income is $911.1 million (2019), against an average of $1.6 billion.
• Across the five-year window, Equity Income surged 100.0% in 2019 and jumped 205331553394.47% in 2020, its largest moves.
• Year by year, Equity Income stood at -$604.7 million in 2018, then surged by 100.0% to $0.89 in 2019, then jumped by 594491215228.45% to $5.3 billion in 2020.
• Per Business Quant, the three latest TAK Equity Income figures stand at $5.3 billion (Q3 2020), $1.8 billion (Q1 2020), and $0.89 (Q1 2019).